Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 381

Results For "company"

4376 News Found

Sanofi to invest up to US $ 60 million in Gyroscope
Startup | November 09, 2021

Sanofi to invest up to US $ 60 million in Gyroscope

A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).


First clinical use of Lucent 3D Lumber successful
Medical Device | November 09, 2021

First clinical use of Lucent 3D Lumber successful

The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence


Divis Labs PAT at Rs 606.46 cr. in Q2FY22
News | November 08, 2021

Divis Labs PAT at Rs 606.46 cr. in Q2FY22

Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.


Govt places orders for one crore doses of ZyCoV-D
News | November 08, 2021

Govt places orders for one crore doses of ZyCoV-D

It is the world’s first DNA-based Covid vaccine


Novavax files emergency use listing with WHO for Covid-19 vaccine
Biotech | November 05, 2021

Novavax files emergency use listing with WHO for Covid-19 vaccine

All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO


CorporateServe launches PharmaSoft 2.0
Digitisation | November 05, 2021

CorporateServe launches PharmaSoft 2.0

The solution helps the pharma enterprises drive efficiencies, save costs, and increase productivity


Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin
Biotech | November 05, 2021

Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin

The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent


Sun Pharma Q2FY22 PAT jumps to Rs 2088.73 Cr
News | November 03, 2021

Sun Pharma Q2FY22 PAT jumps to Rs 2088.73 Cr

Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.


Venus Remedies H1 net profit rises 315%
News | November 03, 2021

Venus Remedies H1 net profit rises 315%

Venus Remedies has reported consolidated financial results for the period ended September 30, 2021


Moderna and Metagenomi partner to develop next-gen in vivo gene editing therapeutics
Biotech | November 03, 2021

Moderna and Metagenomi partner to develop next-gen in vivo gene editing therapeutics

The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies